The purpose of the study is to find out whether the new medicine can improve breathing and reduce serious flare‑ups compared with the placebo. People who join will be randomly assigned to one of the two groups, and neither the participants nor the study staff will know which treatment each person receives (double‑blind). Over several months, participants will come to the clinic for routine visits where their lung function, symptoms and overall health will be checked.

During the study, participants will receive the injections at set intervals and will have simple breathing tests, such as measuring forced expiratory volume in one second (FEV1), which shows how much air can be exhaled quickly. They will also answer short questionnaires about how they feel, and will have basic safety checks like blood tests and a quick heart rhythm check (ECG). All of this information helps researchers see if the medicine works and is safe.

During the study, participants will be assigned to receive either depemokimab or a placebo through a subcutaneous injection, which is a shot given just under the skin. The study is designed so that neither the participants nor the researchers know which treatment is being administered. This approach helps ensure that the results are as accurate as possible.

The purpose of the study is to find out if using targeted oxygen therapy can reduce the risk of death within 30 days compared to standard care. Participants in the study will receive one of the oxygen therapies, and some may also receive medications like Berodual (containing fenoterol hydrobromide and ipratropium bromide), Salbutamol, or Medicinal Oxygen to help with breathing. These treatments are given through inhalation, which means they are breathed in using a device called a nebulizer or as a compressed gas.

The study will follow participants over a period to monitor their health outcomes, such as survival rates at different time points, the length of hospital stays, and the need for additional breathing support like non-invasive ventilation (NIV) or mechanical ventilation. The goal is to improve the care and outcomes for patients with AECOPD by determining the most effective oxygen therapy approach.

The study has two groups. One group receives erdosteine plus standard care, and the other group receives standard care alone. The study lasts about 4 weeks. During this time, blood samples are taken before and after treatment so researchers can compare changes in substances and cell signals related to lung disease, inflammation, and the immune system. These include GPX2, a body protein linked to protection against cell damage, as well as other signs of immune activity and oxidative stress, which means damage caused by harmful molecules in the body.

The purpose of this study is to compare how lung function changes over three years in patients taking metformin compared to those taking placebo. The study will measure lung function using a breathing test that checks how much air a person can force out of their lungs in one second. Participants will need to have a specific type of lung damage called emphysema, which is a form of lung tissue damage that can be seen on imaging scans. They must also have experienced a certain level of decline in their lung function over the past few years.

The study will last for three years, during which participants will take the assigned medication daily. Throughout this time, various measurements will be taken at regular intervals, including breathing tests, blood and urine samples, questionnaires about breathing difficulties and quality of life, and walking tests. Participants will be monitored for any changes in their lung condition, including worsening episodes of breathing problems, doctor visits, and hospital stays. The study will also track the development of other health conditions that might occur during the follow-up period.

The purpose of this study is to see whether Tozorakimab can reduce the number of times COPD symptoms suddenly get worse, which are called exacerbations. These exacerbations are episodes when breathing problems become more severe than usual and may require additional treatment or even hospitalization. The study will compare two different amounts of Tozorakimab given as an injection under the skin to placebo, which will be added to the standard medications that participants are already taking for their COPD.

The study will last for about 52 weeks. During this time, participants will receive regular injections of either Tozorakimab or placebo, and doctors will monitor how often their COPD symptoms worsen and how severe these episodes are. The study focuses on people who have had at least two moderate episodes or one severe episode of worsening COPD symptoms in the past year, who are former smokers, and who continue to have symptoms despite using their regular COPD medications.

The study medication tezepelumab is given as a subcutaneous injection using a pre-filled syringe. Some participants will receive tezepelumab, while others will receive a placebo. Neither the participants nor their doctors will know which treatment is being given during the study.

The treatment period will last for 76 weeks, during which participants will receive regular injections of either tezepelumab or placebo. Throughout the study, doctors will monitor participants’ breathing ability, symptoms, and how often they experience COPD flare-ups. The study will also track any changes in participants’ quality of life and their ability to perform daily activities.

The study involves patients who have moderate to severe COPD and show specific signs of inflammation in their blood. During the study, participants receive either dupilumab (also known as SAR231893) or a matching placebo as injections under the skin for 24 weeks. The medication is provided in pre-filled syringes, and participants continue taking their regular COPD medications throughout the study.

The research uses special lung imaging techniques to examine how the treatment affects mucus in the airways. High-resolution Computed Tomography (HRCT) scans are used to look at changes in the lungs over the course of treatment. The study also monitors the safety of the treatment and any changes in breathing ability.

During the study, participants will be monitored for changes in their breathing and general health. The process includes a six-month period where the medication is taken, followed by a six-month observation period to see how the body responds after the treatment ends. The study also looks at respiratory tract infections, which are illnesses affecting the nose, throat, or lungs, and how they relate to the worsening of COPD. Additionally, aspects such as physical activity, body composition, and overall quality of life will be observed throughout the duration of the study.

The purpose of the study is to find out if the Arexvy vaccine can strengthen the body’s natural defense system in people with lung disease who are at higher risk for severe breathing infections. The researchers want to see if giving Arexvy can help the body respond better to the Prevenar 20 vaccine when they are given at the same time or close together. They will also look at whether Arexvy provides broader protection against various breathing infections and helps control viruses that may stay in the body for a long time.

Participants in this study will receive injections of the vaccines in their arm muscle. Some people will get both vaccines at the same time, while others will receive them at different times. The study will involve blood sample collections at different time points to measure how well the immune system, which is the body’s defense against infections, responds to the vaccines. The researchers will look at specific markers in the blood that show how active the immune system is and measure the levels of protective proteins called antibodies that the body makes after vaccination. The study will follow participants for several months after they receive the vaccines to see how long the protection lasts.

The purpose of this study is to evaluate the long-term effect of tozorakimab in reducing severe flare-ups of the lung disease in people who used to smoke. The study will also look at how safe the medication is when used over a longer period of time. This is an extension study, which means it is designed for people who have already participated in earlier studies of the same medication and completed their treatment without stopping early.

Participants who join this study will continue receiving the same type of treatment they were on in the previous study for up to 52 weeks. They will attend regular clinic visits where doctors will check their lung function, ask about any breathing problems or flare-ups, and monitor for any side effects. The study will track how often participants experience severe flare-ups that require emergency room visits or hospital stays, and will measure how long it takes before these serious episodes occur. Blood samples may be collected to measure the amount of medication in the body and to check how the immune system responds to the treatment.

The purpose of this study is to look at the long-term safety and how well people tolerate tozorakimab when it is added to their standard care. This is an extension study, which means it is designed for people who have already participated in earlier studies of this medication. The study will continue to give tozorakimab to participants to see if it remains safe over a longer period of time. The medication will be given regularly over a period that can last up to 36 months.

During the study, participants will receive tozorakimab and will be monitored for any side effects or health changes. The study team will collect information about any adverse events that occur, perform laboratory tests, and track how participants are doing overall. This information will help researchers understand whether tozorakimab is safe for long-term use in people with COPD who have experienced exacerbations.

During the study, participants will continue taking their regular maintenance medications for their lung disease while also receiving either Fexlamose or placebo through inhalation. The treatment period lasts for 28 days, which is 4 weeks. Throughout this time, researchers will measure how well participants can breathe by checking their lung function, specifically looking at how much air they can force out of their lungs in one second. They will also use a computed tomography scan, which is a special type of imaging test that takes detailed pictures of the lungs, to see if there are any changes in the lung tissue. Additionally, participants will complete questionnaires about how their breathing problems affect their daily life and overall health.

The study will monitor participants for any side effects or health changes that might occur during treatment. This includes regular blood tests, urine tests, and measurements of oxygen levels in the blood. Doctors will also check the CT scans to look for any specific changes in the lungs that might be related to the treatment. The entire study is expected to last from early 2026 until the end of 2026, during which time participants will have several visits to the study site for assessments and monitoring.

The purpose of this research is to understand how this inhaled medication affects heart and lung function compared to placebo. The study will use special imaging techniques including magnetic resonance imaging to look at the heart’s size and function. It will also measure how much air remains in the lungs after breathing out using a technique called body plethysmography.

During the study, participants will receive both the medication and placebo at different times through an inhaler device called a metered dose inhaler. The treatment will be given twice daily. Neither the participants nor the doctors will know which treatment is being given at any particular time. This helps ensure that the results are not influenced by expectations about the treatment.

The study medication Tozorakimab will be given as an injection under the skin, alongside the regular COPD treatments that participants are already taking. Some participants will receive Tozorakimab while others will receive placebo, in addition to their standard COPD medications. Participants may also use salbutamol, a rescue inhaler medication that helps to quickly relieve breathing difficulties when needed.

The study will last for 52 weeks, during which participants will need to attend regular clinic visits for health assessments. Throughout the study, doctors will monitor how often participants experience COPD flare-ups, which are periods when their symptoms become notably worse than usual. These flare-ups can range from moderate to severe and may require additional medical treatment.

The main purpose of this study is to determine if Verekitug can reduce the number of COPD flare-ups (also called exacerbations) that patients experience. During these flare-ups, COPD symptoms become worse than usual, often requiring additional medical treatment. The study will involve patients who have already experienced such flare-ups in the past and are currently using standard COPD medications.

The treatment period will last for 108 weeks (approximately two years). Throughout the study, participants will receive regular injections of either Verekitug or placebo, while continuing their usual COPD medications. The study will monitor how well participants breathe, their quality of life, and any side effects they may experience. Blood samples will be taken to measure how the medication works in the body.

The main purpose of this research is to determine if AZD6793 can reduce how often COPD symptoms get significantly worse (known as exacerbations) compared to placebo. The study will involve different groups of participants who will receive either different doses of AZD6793 or placebo tablets.

The treatment period will last 24 weeks, during which participants will take their assigned medication while continuing their regular breathing medications. Throughout the study, doctors will monitor participants’ breathing ability, symptoms, quality of life, and overall health. They will also check how the body handles the medication and watch for any potential side effects.

Participants in the study will receive one dose of the nasal spray, and the main focus will be on observing any changes in their ability to perform physical activities. The study will measure the distance participants can walk and use a scale called the Borg scale to evaluate their level of exertion or breathlessness during physical activity. The study aims to provide insights into whether this nasal spray can help improve the physical capabilities of those with COPD.

The trial is designed to include both males and females aged between 18 and 64 years who have been diagnosed with COPD according to standard criteria. The study will take place over a period of time, with the goal of understanding the potential benefits of using oxymetazoline nasal spray for improving the quality of life for individuals with COPD.

The main purpose of this study is to determine if tezepelumab can reduce the number of COPD flare-ups (also called exacerbations) in patients. During the study, participants will receive either tezepelumab or placebo through subcutaneous injection using a pre-filled syringe. The treatment period will last for approximately 76 weeks.

The medication being tested, tezepelumab (also known as MEDI9929), is already approved for other uses and is being studied to understand if it can help people with COPD. Throughout the study, doctors will monitor how well the treatment works and check for any side effects. Participants will need to continue using their regular COPD medications during the study period.

The purpose of the study is to see how this medication affects the way patients breathe over a period of one month. Participants will use the inhaler as part of their daily routine. The study will observe changes in their breathing patterns, including how complex and variable their breathing is. This will help researchers understand if the medication can improve the breathing of people with stable COPD.

Throughout the study, participants will have their breathing measured at different times to see how it changes with the use of the medication. The study will also look at other aspects of lung function and symptoms, such as how often and how deeply patients breathe, and how they feel in terms of breathlessness. This information will help determine the effectiveness of the medication in managing COPD symptoms.

The treatment involves receiving a single dose of Prolastin or placebo through an intravenous infusion (directly into a vein). The medication will be given along with a standard salt solution (sodium chloride). Patients will be monitored for 7 days after receiving the treatment to see how their body responds, particularly regarding inflammation levels in their blood.

This is a double-blind study, which means neither the patients nor their doctors will know who receives the actual medication and who receives the placebo. The study will measure various markers of inflammation in the blood and track how patients feel during their hospital stay. The treatment’s effects will be evaluated through blood tests and assessment of breathing difficulties.

Participants in the study will receive either Levofloxacin or Piperacillin/Tazobactam as part of their treatment. The study will involve taking samples from the lungs to measure the concentration of the antibiotics. This will be done using three methods: collecting fluid from the lining of the lungs, taking a small tissue sample, and using a technique called in-vivo microdialysis, which involves measuring the drug concentration in the body over a period of time. These methods will help researchers understand how the drugs are distributed in the lungs.

The study will be conducted over a short period, with the main focus on comparing the three methods of measurement. The results will provide valuable information on how these antibiotics work in the lungs of patients with Chronic Obstructive Pulmonary Disease and Cystic Fibrosis, potentially leading to better treatment strategies in the future.

The purpose of the study is to compare how well Atorvastatin works against a placebo in reducing COPD exacerbations. Participants will take the medication or placebo for a period of time, and researchers will monitor their health to see how often exacerbations occur and how long they last. The study will also look at other health aspects, such as lung function, quality of life, and certain markers in the blood that indicate inflammation. These markers include things like the number of white blood cells and levels of proteins that can show how the body is responding to the disease.

Throughout the study, participants will have regular check-ups to assess their lung function and overall health. This includes measuring how much air they can breathe out in one second, known as forced expiratory volume (FEV1), and how far they can walk in six minutes. The study will also track any hospital visits related to COPD. By the end of the study, researchers hope to better understand whether Atorvastatin can be a helpful treatment for people with COPD, potentially improving their quality of life and reducing the frequency of exacerbations.

The purpose of this research is to determine if tozorakimab can reduce the frequency of COPD flare-ups (also called exacerbations) when added to regular COPD treatments. During the study, some participants will receive tozorakimab while others will receive a placebo, in addition to their regular COPD medications. The study will particularly focus on people who previously smoked and have experienced COPD flare-ups in the past.

The treatment period will last for approximately one year, during which participants will receive regular injections of either tozorakimab or placebo. Throughout the study, participants will continue using their regular COPD medications, including inhalers. The study will monitor how often participants experience COPD flare-ups and track changes in their breathing and overall health.

The purpose of the study is to assess the safety and tolerability of the ARO-MUC5AC treatment. Participants will receive either the ARO-MUC5AC Inhalation Solution or a placebo. The study will be conducted over a period of time, during which participants will be monitored for any side effects and changes in their lung function. This will involve regular check-ups and assessments to ensure the treatment is safe and well-tolerated.

Throughout the study, researchers will collect information on how the treatment affects lung function, specifically looking at measures like forced expiratory volume (FEV1) and forced vital capacity (FVC). These are common tests used to assess how well the lungs are working. The study aims to provide valuable insights into the potential benefits and safety of the ARO-MUC5AC Inhalation Solution for people with muco-obstructive lung diseases like asthma and COPD.

Participants in the study will receive either itepekimab or a placebo. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure the results are not biased. The study will last for about a year, during which participants will receive regular injections and attend scheduled visits to monitor their health and the effects of the treatment. The researchers will be looking at how often participants experience COPD exacerbations, which are episodes where symptoms suddenly get worse and may require additional treatment.

Throughout the study, various health assessments will be conducted to ensure the safety and well-being of the participants. These assessments will include checking lung function, monitoring any side effects, and evaluating overall respiratory symptoms. The study aims to provide valuable information on the effectiveness and safety of itepekimab as a potential treatment for COPD, which could lead to improved management of this challenging condition.

The study aims to compare two different approaches for prescribing azithromycin in COPD patients over a 12-month period. In one group, the medication will be prescribed based on standardized management when patients experience severe mucus symptoms. In the other group, the prescription will be based on analyzing the physical properties of the mucus.

During the study, participants will receive azithromycin tablets by mouth, with a maximum daily dose of 500 mg. Throughout the year-long study, patients will have regular check-ups to monitor their breathing symptoms, measure their lung function, and assess their quality of life. The study will track how often patients experience worsening of their COPD symptoms, known as exacerbations, which can range from mild to severe enough to require hospitalization.

The purpose of the study is to evaluate the effectiveness, safety, and how well patients tolerate Itepekimab. Participants in the study will receive either Itepekimab or a placebo through an injection under the skin. The study will last for about a year, during which participants will have regular check-ups to monitor their health and the effects of the treatment. The study aims to find out if Itepekimab can help reduce the frequency of COPD flare-ups and improve lung function over time.

Throughout the study, researchers will also look at other aspects such as changes in breathing tests, the time it takes for the first flare-up to occur, and any side effects that may arise. This information will help determine if Itepekimab is a safe and effective treatment option for people with COPD. Participants will be closely monitored to ensure their safety and well-being throughout the study period.

Participants in the study will be randomly assigned to receive either CHF6001 DPI or a placebo, which is a substance with no active medication. The study will last for 52 weeks, during which participants will continue their regular maintenance therapy while also using the study medication. The main goal is to see if CHF6001 DPI can reduce the number of moderate and severe flare-ups of COPD and Chronic Bronchitis compared to those who receive the placebo. Throughout the study, participants will be monitored for any changes in their condition and any side effects they may experience.

By the end of the study, researchers aim to gather information on how CHF6001 DPI affects the overall health and quality of life of individuals with COPD and Chronic Bronchitis. This includes looking at changes in symptoms, lung function, and the need for additional medication. The findings from this study could help improve treatment options for people living with these chronic respiratory conditions.

The purpose of the study is to evaluate how effective and safe two different doses of CHF6001 DPI are when added to the usual maintenance therapy for COPD. This maintenance therapy typically includes a combination of inhaled corticosteroids (ICS), long-acting beta-agonists (LABA), and long-acting muscarinic antagonists (LAMA). The study will last for 52 weeks, during which participants will be randomly assigned to different groups. Some will receive CHF6001 DPI along with their regular treatment, while others will receive Roflumilast or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving which treatment until the study is completed.

Throughout the study, participants will be monitored to see how the treatments affect their COPD symptoms, particularly the frequency and severity of flare-ups, also known as exacerbations. The study will also assess changes in lung function and quality of life. By the end of the study, researchers hope to determine whether adding CHF6001 DPI to the standard COPD treatment can help reduce the number of moderate and severe exacerbations in patients with COPD and chronic bronchitis.

The purpose of the study is to find out if using corticosteroids can increase the number of days patients can breathe on their own without the help of a ventilator within 28 days. Patients in the study will receive either the corticosteroid treatment or a placebo, and their progress will be monitored to see how long they need ventilator support and how well they recover. The study will also look at other factors like the length of hospital stay and any side effects that might occur.

Participants will be closely observed during their time in the hospital, and the study will last for a period of up to five days for the treatment phase. The researchers aim to gather information that could help improve the care and treatment of patients with severe COPD in the future. The study is expected to continue until early 2027, with results being analyzed to determine the effectiveness of the treatment.

The purpose of the study is to assess whether a personalized diagnostic and therapeutic strategy can effectively reduce the use of antibiotics compared to the usual treatment methods. This approach involves using advanced techniques like MULTIplex PCR and measuring procalcitonin levels, which are indicators of bacterial infection, along with observing the appearance of sputum, a substance produced in the lungs. The study will be conducted in a controlled, randomized manner, meaning participants will be randomly assigned to different treatment groups to ensure unbiased results.

Participants in the study will receive treatment for up to seven days, and their progress will be monitored over a period of 28 days. The main goal is to determine the number of days patients can live without antibiotics by the end of this period. Secondary outcomes include the number of days patients require antibiotics, the incidence of hospital-acquired infections, and the overall duration of hospital stays. The study will also track the occurrence of any additional COPD exacerbations and assess patients’ quality of life using the COPD Assessment Test (CAT) at 90 days. The trial is expected to conclude in early 2025.

The purpose of the study is to see if the new HFO version of the inhaler works as well as the traditional HFA version in improving lung function in people with COPD. Participants in the study will use each type of inhaler for a period of time, and their lung function will be measured to assess the effectiveness of the treatments. The study will last for about four weeks, and participants will switch between the different inhalers during this time.

Throughout the study, participants will be monitored for any changes in their health, including vital signs like blood pressure and heart rate. The study aims to ensure that the new HFO inhaler is just as safe and effective as the current HFA inhaler for people with COPD. This research is important for potentially improving treatment options for those living with this chronic lung condition.

Participants in the study will receive either Astegolimab or a placebo. The study will last for 52 weeks, during which the effects of the treatment on COPD symptoms will be closely monitored. The study will also look at how the treatment affects the quality of life of the participants, using a questionnaire designed to measure respiratory health. Additionally, the study will assess changes in lung function and the occurrence of any side effects.

Throughout the study, participants will continue their usual COPD maintenance therapy, which may include medications like inhaled corticosteroids, long-acting beta2-agonists, and long-acting muscarinic antagonists. The goal is to see if adding Astegolimab to these standard treatments can provide additional benefits in managing COPD. The study will also measure the levels of Astegolimab in the blood and check for any immune responses to the drug.

The purpose of this study is to evaluate how safe and well-tolerated itepekimab is over a longer period in people who have already participated in previous studies involving this treatment. Participants in this study will have previously completed a treatment period in one of two earlier clinical studies. During the study, participants will receive either itepekimab or a matched placebo, which is a substance that looks like the treatment but does not contain the active ingredient. The study will monitor participants for any side effects or reactions to the treatment, as well as measure the levels of itepekimab in the blood.

Throughout the study, researchers will also observe how often participants experience flare-ups of their COPD symptoms, known as acute exacerbations, and how long it takes for these flare-ups to occur. Additionally, changes in lung function and quality of life from the baseline of the previous studies will be assessed. The study aims to provide valuable information on the long-term use of itepekimab in managing COPD symptoms and improving patient outcomes.

Participants in the study will receive either Tezepelumab or a placebo, which is a substance with no active medication. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving Tezepelumab and who is receiving the placebo. This helps ensure that the results are not influenced by expectations about the treatment. The study will last for a period of 20 weeks, during which the effects of the medication on airway inflammation will be closely monitored.

The main goal of the study is to evaluate how Tezepelumab affects a specific type of inflammation in the bronchial tissue, which is part of the airways. By understanding this, researchers hope to find better ways to manage COPD and improve the quality of life for those affected by this condition. Participants will receive the medication through a subcutaneous injection, which means it is given under the skin. The study will help gather important information about the potential benefits of Tezepelumab for people living with COPD.

Participants in the study will receive either Dronabinol or a placebo, which looks like the medication but does not contain the active ingredient. The study is designed to compare the effects of Dronabinol with the placebo to see if there is a difference in how patients feel and function in their daily lives. The trial will last for a period of four weeks, during which participants will switch between taking Dronabinol and the placebo without knowing which one they are taking at any given time.

The main goal of the study is to assess whether Dronabinol can reduce the discomfort of daily breathlessness and improve daily activities for people with COPD. The study will also look at other aspects of health, such as anxiety, depression, sleepiness, and physical activity, to understand the overall impact of the treatment. Participants will be monitored through various tests and questionnaires to gather information on their symptoms and overall well-being.

The purpose of this study is to understand how itepekimab works in the body, particularly in reducing inflammation in the airways of people with COPD. The study is divided into two parts. In the first part, researchers will look at changes in gene activity in the airways of former smokers with COPD after receiving itepekimab. In the second part, they will confirm these findings in a similar group of participants. The medication is given as a solution for injection under the skin using a pre-filled syringe.

Participants in the study will receive either itepekimab or a placebo. The study will monitor changes in gene activity and other markers of inflammation in the airways over time. This research aims to provide insights into how itepekimab may help manage COPD by reducing airway inflammation, potentially leading to better treatment options for patients with this condition.

The purpose of the study is to compare the effectiveness, safety, and how well people tolerate these two treatments. Participants in the study will be randomly assigned to receive either CHF 5993 or CHF 1535. The study will last for 52 weeks, during which participants will use the inhaler daily. Throughout the study, participants will have regular check-ups to monitor their lung function and overall health. The main goal is to see if CHF 5993 can improve lung function before taking the daily dose compared to CHF 1535.

Participants will also be monitored for any side effects or health issues that may arise during the study. This includes tracking any worsening of COPD symptoms, known as exacerbations, and any other health events. The study aims to provide valuable information on which treatment may be more beneficial for people living with COPD.

The purpose of the study is to assess how well these treatments work in improving heart and lung health in people with COPD. Participants will be randomly assigned to receive one of the treatments or a placebo. The study will last for up to 36 months, during which participants will use the inhalers as directed and attend regular check-ups to monitor their health. The study aims to determine the time it takes for participants to experience severe heart or lung-related events, such as worsening of COPD symptoms or heart problems.

Throughout the study, participants will be closely monitored to ensure their safety and to gather information on how the treatments affect their condition. The results of this study will help to understand the benefits and risks of using these inhaler medications for managing COPD and improving overall heart and lung health.